Compare QUALCOMM, Inc. (QCOM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs Tango Therapeutics Inc. — how do they compare? QUALCOMM, Inc. trades at $170.99 (market cap $188.86B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: QUALCOMM, Inc. is far larger — about 50.4× Tango Therapeutics Inc.'s market cap, and QUALCOMM, Inc. pays a 2.08% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold QUALCOMM, Inc. for 87 Days and Tango Therapeutics Inc. for 0 Days on average.
| QCOM | TNGX | |
|---|---|---|
Market Cap | $188.86B | $3.75B |
Volume | 12,280,716 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $251.10 | $32.90 |
52-Week Low | $124.07 | $7.50 |
Typical Hold Time | 87 Days | 0 Days |
Enterprise Value | $195.82B | $2.77B |
Dividend Yield | 2.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $174.43, down 0.61% today, with a bearish technical signal despite recent AI-driven optimism. The company reported mixed Q2 2026 earnings, missing EPS estimates at $2.21 versus $2.23 expected, but maintains strong profitability with 54.23% gross margins and 21.01% net income margin. Recent news highlights a transformative $60 billion Amazon AI partnership, boosting data center ambitions beyond its core handset business.
QCOM's valuation appears reasonable with a P/E of 20.21, trading below the analyst consensus price target of $204.48. Key opportunities include AI data center growth and automotive expansion, while risks involve smartphone dependency and competitive pressures. Wall Street sentiment is mixed with 43.48% buy ratings, but the stock offers potential upside if AI bets materialize.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
